, Tracking Stock Market Picks
Enter Symbol:
Allergan, Inc. (AGN) [hlAlert]

up 402.10 %

Allergan, Inc. (AGN) rated Buy with price target $70 by Brean Murray

Posted on: Thursday,  Feb 4, 2010  4:25 PM ET by Brean Murray

Brean Murray rated Buy Allergan, Inc. (NYSE: AGN) on 02/04/2010. Previously Brean Murray rated Buy Allergan, Inc. (NYSE: AGN) on 12/17/2009.,
when the stock price was $60.94. Since then, Allergan, Inc. has gained 402.10% as of 11/24/2015's recent price of $305.98.
If you would have followed the previous Brean Murray's recommendation on AGN, you would have gained 402.1% of your investment in 2168 days.

Allergan, Inc. is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics and medical devices. The Company is engaged in discovering, developing and commercializing specialty pharmaceutical, medical device and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in more than 100 countries globally. In January 2007, the Company completed the acquisition of Groupe Corneal Laboratoires (Corneal). In October 2007, the Company completed the acquisition of Esprit Pharma Holding Company, Inc. (Esprit). In July 2008, the Company acquired the Aczone (dapsone) gel 5% from QLT USA, Inc. (QLT), a wholly owned subsidiary of QLT Inc. The Company operates in two business segments: specialty pharmaceuticals and medical devices.

Our equity research department is focused on fundamental analysis across the universe of over 200 small/mid cap stocks in our five target sectors. We are committed to providing proprietary action-oriented research to our institutional clients. Small cap growth focus. Our primary area of concentration is growth stocks with market capitalization of $200 million to $5 billion. Global perspective. We are covering U.S. listed stocks for companies domiciled in the U.S., China, Europe and Latin America, with our biggest concentration in the US and China. We were one of the first banks to aggressively expand our research to China and we believe we created one of the premier research franchises in small cap, U.S. listed Chinese companies to complement our strong domestic coverage. Disciplined stock selection. Our research analysts are focused on performing extensive bottoms up due diligence on companies under our coverage by leveraging their industry and management contacts. By combining our bottoms up work with our sector views we seek to generate a consistent flow of high conviction ideas for our clients. Diversified coverage. Our areas of expertise include technology, consumer, healthcare, resources and China small cap. We provide our clients with company-specific as well as sector-specific research across our target sectors.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/4/2010 4:25 PM Buy
57.15 70.00
as of 12/31/2010
1 Week up  2.77 %
1 Month up  7.68 %
3 Months up  7.25 %
1 YTD up  13.25 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/17/2009 8:25 AM Buy
60.94 75.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy